1. Home
  2. IZM vs IMNN Comparison

IZM vs IMNN Comparison

Compare IZM & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICZOOM Group Inc.

IZM

ICZOOM Group Inc.

HOLD

Current Price

$0.50

Market Cap

12.3M

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.16

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZM
IMNN
Founded
2011
1982
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
11.0M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
IZM
IMNN
Price
$0.50
$3.16
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
27.6K
16.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.37
52 Week High
$2.74
$9.32

Technical Indicators

Market Signals
Indicator
IZM
IMNN
Relative Strength Index (RSI) 14.35 43.16
Support Level N/A $3.03
Resistance Level $2.74 $3.16
Average True Range (ATR) 0.07 0.23
MACD -0.01 -0.01
Stochastic Oscillator 0.51 20.63

Price Performance

Historical Comparison
IZM
IMNN

About IZM ICZOOM Group Inc.

ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: